Danish company BioPorto announced on Tuesday that it was extending its strategic collaboration with Roche Diagnostics, Roche's in vitro diagnostics subsidiary.

BioPorto, whose test for the biomarker of pediatric acute renal failure was recently approved in the USA, states that the distribution agreement with Roche will now include the cobas c 503 analytical unit.

Previously, the partnership covered the cobas c 501 and c 502 modules.

BioPorto, which develops tests for diagnosing human diseases, specializes in technologies for identifying and monitoring acute kidney injury.

Copyright (c) 2024 CercleFinance.com. All rights reserved.